Industry: starting next year, the golden age of the pharmaceutical sector will restart

Recently, the disclosure of the third quarterly report of A-share listed companies came to an end
.
Excluding individual companies that postpone their performance disclosures, Wind statistics show that in the first three quarters, a total of 4528 listed companies disclosed their three-quarter reports.
Revenue and net profit attributable to the parent company were 46.
79 trillion yuan and 4.
06 trillion yuan, respectively, with a year-on-year growth rate of 22.
06.
% And 24.
99%
.
Among them, the sci-tech innovation board company's three quarterly reports have outstanding performance, including biomedicine, new energy, new-generation information technology, energy conservation and environmental protection, new materials and high-end equipment manufacturing industries, all showing strong growth momentum
.
The agency believes that performance uncertainties will be eliminated.
In the future, more attention will be paid to the subdivisions of the improvement of the economy, and the low value of the allocation will still be concerned
.
Now that the end of the year is approaching, and the valuation of the pharmaceutical sector is gradually returning to a reasonable range, does it mean that the sector has an opportunity for allocation? How should investors choose? Many fund managers have expressed their opinions
.
China Merchants Fund believes that under the situation of a high base last year, the performance of pharmaceutical companies in the third quarter has clearly differentiated, and it is expected that the trend of differentiation will continue in the market outlook
.
However, the pre-adjustment of the pharmaceutical sector is relatively sufficient, and the valuation premium has dropped significantly.
The valuation switch market after the third quarterly report is worth looking forward to
.
Chuangjin Hexin Pharmaceutical Consumer Stock Fund stated in its third quarterly report that although stock prices have fallen since the beginning of this year, the competitiveness of many pharmaceutical companies has increased, and they are basically industry leaders.
The continuous R&D investment and the continuous enrichment of product pipelines will increase the company’s competitiveness.
Long-term value and valuation adjustments lay a healthy foundation for subsequent trends
.
Looking forward to the fourth quarter, the performance of key pharmaceutical companies is expected to maintain a rapid growth momentum.
The valuations of many companies next year will be more reasonable.
It is expected that there will be a valuation switch in the fourth quarter
.
Tianhong Fund said that the three quarterly reports have ended and will enter the longest period of performance vacuum in a year.
At present, it is still optimistic about the future development trend of the pharmaceutical industry
.
2021 is a year of greater pressure in the pharmaceutical sector, and it is expected that starting from 2022, the golden period of the pharmaceutical sector will be reopened
.
The fourth quarter of this year will be a good time for investment in the pharmaceutical industry
.
The manager of Tianhong Pharmaceutical Innovation Fund believes that policy is an important factor for the suppression of the pharmaceutical industry in 2021.
Starting from 2022, the policy development period has ended, and the sixth round of centralized drug procurement has been carried out.
The impact of the policy may be even greater.
Localized and individualized
.
At the same time, the relative advantages of the pharmaceutical industry will gradually become more prominent in the future.
In the future, the pharmaceutical industry will become more competitive in the post-epidemic era due to its rigid needs and mandatory attributes
.
In addition, the increase in population structure and government investment is a long-term catalyst for the pharmaceutical industry
.
In the future, the long-term nature of the pharmaceutical industry will become more prominent, and the pharmaceutical industry may take the lead in revaluation
.
The fund manager is optimistic about three investment directions.
One is the innovation sector.
In 2022, China’s innovative pharmaceutical companies are about to enter the world.
This will be a turning point for China’s innovative pharmaceutical companies; second, the domestic substitution trend of China’s pharmaceutical industry chain It will continue, including from upstream to downstream, from production to products; thirdly, there will still be investment opportunities in sub-sectors that are misunderstood by policies of the pharmaceutical industry in the future
.
To sum up, the pharmaceutical sector is ushering in a good allocation opportunity.
Fund managers are generally optimistic about the trend of the fourth quarter and next year, especially optimistic about the layout opportunities of the pharmaceutical sector in 2022
.
Next year or a year full of opportunities, as a rigidly-needed pharmaceutical sector, under the background of population aging, consumption upgrades, and related investment increase, there is a certain amount of development space to be tapped
.
From the perspective of specific segments, innovation and domestic substitution are still promising opportunities in the industry.
Companies that actively deploy in such sectors may usher in development opportunities
.